“Durable Maintenance of EASI-90 With Amlitelimab in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Results from the STREAM-AD Phase 2b Trial”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s606, https://doi.org/10.25251/yhn4cs07.